Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma.
Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30-80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half-life and superior antitumour activity compared with etoposide in some experimental models. Thus a phase II trial was done in 25 patients with AIDS-related KS. Teniposide was given by 60-min infusion at 360 mg/m2 every 3 weeks. 10 (40%) showed a partial response, median duration of 9 (6-20) weeks. The main side-effects were leukopenia, thrombocytopenia, nausea and vomiting, alopecia and mucositis.
Schwartsmann
G
G
AIDS and Oncology Unit, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil.
Sprinz
E
E
Kronfeld
M
M
Vinholes
J
J
Sander
E
E
Zampese
M
M
Preger
R
R
Kalakun
L
L
Brunetto
A L
AL
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D004341:Drug Evaluation; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009325:Nausea / Q000139:chemically induced; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D013713:Teniposide